With the launch of five adalimumab biosimilars into the European market since October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), Hyrimoz (Sandoz), and Idacio (Fresenius Kabi)—competition within the already dynamic autoimmune therapy market will only increase. The first biosimilars to launch in this therapy area (infliximab  and Benepali ) have now been available for several years in Europe, and their uptake has been robust. With more adalimumab biosimilars forecast to launch in Europe over the next years, it will be critical for stakeholders active in the immune space to understand the dynamics of how adalimumab biosimilars will affect the uptake of the reference brand, Humira (AbbVie), and other originator biologics. Along with physician familiarity, awareness and perceptions of biosimilars in general, and the launch of adalimumab biosimilars in particular, we explore the drivers of and barriers to the uptake of adalimumab biosimilars in Germany. We discuss promotional efforts, as well as prescriber and nonprescriber profiles, and benchmark the agents against other available biosimilars to better understand the dynamics of the German biosimilar market.
- Are German physicians aware of Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio?
- What is driving and will drive the uptake of adalimumab biosimilars in Germany? What is the current level of use of Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio, and how will this use change over time?
- Have German physicians experienced pressure to prescribe Amgevita, Imraldi, Hulio, Hyrimoz, and/or Idacio to patients?
- What promotional messages are sales representatives using with the reference brand Humira and the adalimumab biosimilars Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio?
Emerging Biosimilars is a three-wave series based on primary research data collected at one, six, and twelve months postcommercial launch. The research captures physicians’ awareness, perceptions, and use of biosimilars, as well as their impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Wave 1: February 2019
Wave 2: July 2019
Wave 3: January 2020
Survey of 30 rheumatologists, 30 gastroenterologists, and 30 dermatologists
Key metrics included
- Unaided and aided awareness of Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio
- Familiarity with and impressions of Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio
- Prescriber and nonprescriber profiles
- Willingness to prescribe Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio
- Performance of Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio on key attributes
- Sales representative frequency, reach, and satisfaction
- Benchmarking against previously launched biosimilars
- Immunology: Adalimumab Biosimilars Launch Tracking (Germany) Wave 3
- Emerging Biosimilars: Adalimumab Biosimilars Launch Tracker (W3)
Author(s): Marta Delgado, PhD
Marta Delgado, is a Business Insight Analyst in the Biosimilars Research team, responsible for the analysis of the biosimilars market across four main therapeutic areas – oncology, endocrinology, immunology and nephrology. Marta holds a in Molecular Neuroscience from University College of London (UCL) and a in Biomedicine from University Pompeu Fabra (UPF), Barcelona. Prior to joining the Biosimilars Research team, Marta worked as a Research Analyst at SKIM, specialising in advanced quantitative studies assessing the potential market opportunities to support life sciences companies in their business decision making.